Tags

Type your tag names separated by a space and hit enter

Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon.
Bull World Health Organ. 2002; 80(7):538-45.BW

Abstract

OBJECTIVE

To evaluate the therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine, and the sulfadoxine-pyrimethamine-amodiaquine combination for the treatment of uncomplicated Plasmodium falciparum malaria in young children in Cameroon.

METHODS

In a randomized study we evaluated the effectiveness and tolerance of (i) sulfadoxine-pyrimethamine (SP) (25 mg/kg body weight of sulfadoxine and 1.25 mg/kg of pyrimethamine in a single oral dose), (ii) amodiaquine (AQ) (30 mg/kg body weight in three divided daily doses), and (iii) the sulfadoxine-pyrimethamine-amodiaquine combination (SP+AQ) (same doses as in the other two treatment groups, given simultaneously on day 0) in young children in southern Cameroon. The parasitological and clinical responses were studied until day 28 in accordance with the modified 1996 WHO protocol for the evaluation of the therapeutic efficacy of antimalarial drugs.

FINDINGS

Of 191 enrolled patients, 6 and 8 were excluded or lost to follow-up before day 14 and between day 14 and day 28, respectively. For the AQ-treated patients, parasitological and clinical evaluation on day 14 showed late treatment failure in 2 of 61 (3.3%) and adequate clinical response with parasitological failure in one (1.6%). There was an adequate clinical response in all patients treated with SP or SP+AQ. Therapeutic failure rates on day 28 were 13.6%, 10.2% and 0% in the SP, AQ, and SP+AQ groups, respectively. Anaemia improved in all three regimens. AQ produced faster fever clearance but was associated with more transient minor side-effects than SP. SP+AQ reduced the risk of recrudescence between day 14 and day 28 but increased the incidence of minor side-effects.

CONCLUSION

SP+AQ can be recommended as a temporary means of slowing the spread of multidrug resistance in Plasmodium falciparum in Africa while the introduction of other combinations, including artemisinin derivatives, is awaited.

Authors+Show Affiliations

Unité de Recherche Paludologie Afro-tropicale, Institut de Recherche pour le Développement, Laboratoire de Recherche sur le Paludisme, Organisation de Coordination pour la Lutte contre les Endémies en Afrique Centrale, Yaoundé, Cameroon.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12163917

Citation

Basco, Leonardo K., et al. "Therapeutic Efficacy of Sulfadoxine-pyrimethamine, Amodiaquine and the Sulfadoxine-pyrimethamine-amodiaquine Combination Against Uncomplicated Plasmodium Falciparum Malaria in Young Children in Cameroon." Bulletin of the World Health Organization, vol. 80, no. 7, 2002, pp. 538-45.
Basco LK, Same-Ekobo A, Ngane VF, et al. Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. Bull World Health Organ. 2002;80(7):538-45.
Basco, L. K., Same-Ekobo, A., Ngane, V. F., Ndounga, M., Metoh, T., Ringwald, P., & Soula, G. (2002). Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. Bulletin of the World Health Organization, 80(7), 538-45.
Basco LK, et al. Therapeutic Efficacy of Sulfadoxine-pyrimethamine, Amodiaquine and the Sulfadoxine-pyrimethamine-amodiaquine Combination Against Uncomplicated Plasmodium Falciparum Malaria in Young Children in Cameroon. Bull World Health Organ. 2002;80(7):538-45. PubMed PMID: 12163917.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. AU - Basco,Leonardo K, AU - Same-Ekobo,Albert, AU - Ngane,Vincent Foumane, AU - Ndounga,Mathieu, AU - Metoh,Theresia, AU - Ringwald,Pascal, AU - Soula,Georges, PY - 2002/8/7/pubmed PY - 2003/8/13/medline PY - 2002/8/7/entrez SP - 538 EP - 45 JF - Bulletin of the World Health Organization JO - Bull World Health Organ VL - 80 IS - 7 N2 - OBJECTIVE: To evaluate the therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine, and the sulfadoxine-pyrimethamine-amodiaquine combination for the treatment of uncomplicated Plasmodium falciparum malaria in young children in Cameroon. METHODS: In a randomized study we evaluated the effectiveness and tolerance of (i) sulfadoxine-pyrimethamine (SP) (25 mg/kg body weight of sulfadoxine and 1.25 mg/kg of pyrimethamine in a single oral dose), (ii) amodiaquine (AQ) (30 mg/kg body weight in three divided daily doses), and (iii) the sulfadoxine-pyrimethamine-amodiaquine combination (SP+AQ) (same doses as in the other two treatment groups, given simultaneously on day 0) in young children in southern Cameroon. The parasitological and clinical responses were studied until day 28 in accordance with the modified 1996 WHO protocol for the evaluation of the therapeutic efficacy of antimalarial drugs. FINDINGS: Of 191 enrolled patients, 6 and 8 were excluded or lost to follow-up before day 14 and between day 14 and day 28, respectively. For the AQ-treated patients, parasitological and clinical evaluation on day 14 showed late treatment failure in 2 of 61 (3.3%) and adequate clinical response with parasitological failure in one (1.6%). There was an adequate clinical response in all patients treated with SP or SP+AQ. Therapeutic failure rates on day 28 were 13.6%, 10.2% and 0% in the SP, AQ, and SP+AQ groups, respectively. Anaemia improved in all three regimens. AQ produced faster fever clearance but was associated with more transient minor side-effects than SP. SP+AQ reduced the risk of recrudescence between day 14 and day 28 but increased the incidence of minor side-effects. CONCLUSION: SP+AQ can be recommended as a temporary means of slowing the spread of multidrug resistance in Plasmodium falciparum in Africa while the introduction of other combinations, including artemisinin derivatives, is awaited. SN - 0042-9686 UR - https://www.unboundmedicine.com/medline/citation/12163917/Therapeutic_efficacy_of_sulfadoxine_pyrimethamine_amodiaquine_and_the_sulfadoxine_pyrimethamine_amodiaquine_combination_against_uncomplicated_Plasmodium_falciparum_malaria_in_young_children_in_Cameroon_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/12163917/ DB - PRIME DP - Unbound Medicine ER -